KR870001416B1 - Manufacturing method of anti-cancerous polypeptide - Google Patents

Manufacturing method of anti-cancerous polypeptide Download PDF

Info

Publication number
KR870001416B1
KR870001416B1 KR1019840005339A KR840005339A KR870001416B1 KR 870001416 B1 KR870001416 B1 KR 870001416B1 KR 1019840005339 A KR1019840005339 A KR 1019840005339A KR 840005339 A KR840005339 A KR 840005339A KR 870001416 B1 KR870001416 B1 KR 870001416B1
Authority
KR
South Korea
Prior art keywords
medium
anticancer
culture
protein
cancerous
Prior art date
Application number
KR1019840005339A
Other languages
Korean (ko)
Other versions
KR860001878A (en
Inventor
신상철
김병각
정재형
Original Assignee
일양약품공업 주식회사
정형식
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일양약품공업 주식회사, 정형식 filed Critical 일양약품공업 주식회사
Priority to KR1019840005339A priority Critical patent/KR870001416B1/en
Publication of KR860001878A publication Critical patent/KR860001878A/en
Application granted granted Critical
Publication of KR870001416B1 publication Critical patent/KR870001416B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/074Ganoderma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An anti-cancerous polypeptide is prepd. by culturing Bacidiomycetes. Thus, Bacidiomycetes is cultured in a medium contg. 50g glucose, 20g peptone, 0.87g KH2PO4, 0.5g MgSO4.7H2O, 0.3g CaCl2, and 10ml B.S.M. in 1 l distilled water (pH=5.0) for 14days. The supernatant obtained from the above culture broth is treated with ethanol to give anti- cancerous polypeptide.

Description

항암성 단백 다당류의 제조방법Method for preparing anticancer protein polysaccharide

제1도는 본 발명에 의하여 제조된 항암성 단백 다당류를 구성하는 단당류의 H.P.L.C.에 의한 크로마토그램.1 is a chromatogram of H.P.L.C. of monosaccharides constituting the anticancer protein polysaccharide prepared according to the present invention.

제2도는 표준 아미노산의 크로마토그램.2 is a chromatogram of standard amino acids.

제3도는 본 발명에 의하여 제조된 단백 다당류의 단백부분을 구성하는 아미노산에 대한 아미노산 자동 분석기에 의한 크로마토 그램이다.3 is a chromatogram by an automatic amino acid analyzer for the amino acids constituting the protein portion of the protein polysaccharide prepared according to the present invention.

본 발명은 한국산 담자균류를 산업용 배지에서 액내배양하므로써 얻어지는 항암작용을 지닌 단백 다당류를 제조하는 방법에 관한 것이다.The present invention relates to a method for producing a protein polysaccharide having anticancer activity obtained by culturing Korean basidiomycete in a liquid medium in an industrial medium.

현재까지 고등균류에 속하는 담자균류의 일부로부터 약요 성분인 수종의 항균성분, 환각성분, 독성분, 콜레스테롤 감소성분에 관하여 연구가 진해되고 있으나, 특히 최근에 와서 항암성분의 연구가 활발히 진행되고 있어 담자균류에 대한 중용성이 높아지고 있다.Until now, research on the antimicrobial, hallucinogenic, toxic, and cholesterol-reducing components of several species, which are important ingredients, has been conducted from some of the fungi belonging to the higher fungi, but the anti-cancer component has been actively studied recently. Neutrality for these products is increasing.

담자균류에 함유된 유효성분에 관한 연구로는 보스(Bose)에 의한 1955년 담자균류에서 수종의 항암성분에 대한 보고와 캐탈포모(Catalfomo) 등에 의한 1964년 담자균류 중 psllocybe 속의 균을 인공 배양한 것 등이 있다. 최근 일본에서는 담자균류의 항암성분에 대한 연구가 활발히 진행되어 담자균류 중 표고버섯 [Lentlnus edodes(Berk) slnger]에서 추출한 레티난(lentlnan)이 사르코마(Sarcoma)-180에 대하여 강한 항암작용이 있음을 밝힌바 있다.Studies on the active ingredients contained in basidiomycetes include the report of anti-cancer components of several species from basidiomycetes in 1955 by Bos and artificial culture of psllocybe bacteria in 1964 basidiomycetes by Catalfomo et al. Things. Recently, active studies on anticancer components of basidiomycetes have been carried out, and retinan (lentlnan) extracted from shiitake mushrooms [Lentlnus edodes (Berk) slnger] has strong anticancer activity against Sarcoma-180. I have said.

또한 쯔가고시 등은 1974년에 일본산 구름버섯 [Corlolus Verslcolor(Fr.) Quel.] 성분중의 하나인 단백결합 다당류가 사르코마-180에 대한 항암작용이 있음을 발표하였으며, 미야자끼 등은 1981년도에 만년버섯(Ganoderma lucldum)에서 추출한 다당류가 사르코마-180에 대하여 항암작용이 있음을 발표하였다.In 1974, Tugagoshi et al. Announced that protein-bound polysaccharides, one of the ingredients of the Japanese cloud mushroom [Corlolus Verslcolor (Fr.) Quel.], Have anticancer activity against Sarcoma-180. In fiscal year, polysaccharides extracted from Ganoderma lucldum were reported to have anticancer activity against Sarcoma-180.

일본산 담자균류의 배양 및 항암성분의 추출에 관한 것으로는 국내특허 공고번호 제81-944호 및 제98-1708호 등이 있다.The cultivation of Japanese basidiomycetes and the extraction of anticancer components include Korean Patent Publication Nos. 81-944 and 98-1708.

따라서, 본 발명자들은 국내에서 자생하는 만년 버섯인 가노데르마 루시둠(Fr.) 카르스텐 [Ganoderma lucldum(Fr.) Karsten]의 배양 및 항암성분에 관하여 연구를 거듭한 결과 본 발명을 완성하게 되었다.Accordingly, the present inventors have completed the present invention as a result of culturing and anticancer component of Ganoderma lucldum (Fr.) Karsten, a native mushroom grown in Korea. .

즉, 본 발명의 목적은 만년버섯의 배양방법 및 항암성분의 추출방법을 제공하는데 그 목적이 있는 것이다.That is, an object of the present invention is to provide a method of cultivating a mushroom and a method for extracting anticancer components.

본 발명에서 사용한 만년버섯의 균사체는 본발명자 등이 학생 교육 및 연구목적을 위하여 서울대학교 약학 대학에 보존되고 있는 자유로이 분양가능한 표준균주로써, 본 발명자 등은 이 균사체를 산업용 배지를 이용하여 액내 배양조건을 연구하고, 액내 배양에서 생성되는 균체량을 중가시키기 위한 각종 배양조건을 검토 및 확립한 후 배양된 균사체로부터 추출한 성분의 항암효과를 사르코마-180에 대한 증식 저지효과로서 측정하여 확인하므로써 본 발명을 완성하게 되었다.The mycelia of the mushrooms used in the present invention are freely available standard strains of the present inventors, which are preserved at the College of Pharmacy, Seoul National University for student education and research purposes. The present invention is carried out by reviewing and establishing various culture conditions for increasing the amount of cell mass produced in the liquid culture, and measuring and confirming the anticancer effect of the components extracted from the cultured mycelium as a proliferation inhibitory effect against Sarcoma-180. It was completed.

배지조성Badge composition

1) 종균용 배지1) spawn medium

감지인퓨전 10g, 글루코오즈 50g, 펩톤 5g, 효모액기스 5g, K2HPO41.5g, MnSO40.5g에 증류수를 가하여 1l로 하고, 0.1N HCl로 pH를 5.5로 조절한 후 한천 20g을 넣어서 멸균한 후 사면 배지를 제조한다.Sense infusion 10g, glucose 50g, peptone 5g, yeast extract 5g, K 2 HPO 4 1.5g, MnSO 4 0.5g added distilled water to 1l, pH adjusted to 5.5 with 0.1N HCl and sterilized by adding 20g agar Afterwards, the slope medium is prepared.

* 감자 인퓨전은 감자 10g을 썰어서 물 500g에 넣고 끓인 후 짜서 만든다.* Potato Infusion is made by slicing 10g of potatoes and putting it in 500g of water and boiling.

2) 액내 진탕 배양용 배지의 제조2) Preparation of Aqueous Shake Culture Medium

후술하는 배지번호 1-9, 총 81종의 배지를 각 성분에 따라서 제조하고 멸균하여 액내 진탕용 배지로 사용한다.A total of 81 kinds of medium numbers 1-9, which will be described later, are prepared according to each component, and sterilized, and used as a medium for shaking in liquid.

배양방법Culture method

1) 종균배양1) spawn culture

저장균주의 균사체를 무균적으로 분리하여 종균용 사면배지에 이식하고 24±1℃에서 1주일간 배양하여 종균을 제조한다.The mycelia of the stock strains are aseptically isolated, transplanted into a spawn medium for spawn and incubated for one week at 24 ± 1 ° C to prepare spawn.

2) 1차 액내 배양2) Primary incubation

사면배지의 균사를 무균적으로 분리하여 액내배양용 배지소량을 가하여 블렌더(blender)로 균질화한 후 125ml의 액내배양용 배지를 가한 500ml 삼각 플라스크에 이식하여 24±1℃에서 180rpm의 속도로 오비탈 진탕 배양장치에서 일주일간 배양한다.Aseptic mycelia of the slope medium were added as a small amount of incubation medium, homogenized with a blender, and then transplanted into a 500 ml Erlenmeyer flask to which 125 ml of incubation medium was added, followed by orbital shaking at a speed of 180 rpm at 24 ± 1 ° C. Incubate for one week in the incubator.

3) 2차 액내 배양3) Secondary liquid culture

균사체를 포함한 배양액 전체를 10초간 균질화한 후 무균 피펫으로 10ml씩 취하여 액내 배양용 배지 250ml를 가한 1l 삼각 플라스크에 이식하여 24±1℃에서 180rpm의 속도로 오비탈 진탕 배양장치에서 2주일간 배양한다.After homogenizing the whole culture solution containing the mycelium for 10 seconds, take 10ml each with a sterile pipette and transplant into a 1l Erlenmeyer flask to which 250ml of culture medium was added and incubate for 2 weeks in an orbital shaking culture apparatus at a speed of 180rpm at 24 ± 1 ℃.

항암성분의 추출 및 분리Extraction and Separation of Anticancer Ingredients

박등(1979)의 방법에 따라 배양액을 감압 여과하여 여액과 균사체를 분리하고, 여액을 농축하여 농축액부피의 3배량의 에탄올을 가해 4℃에서 1일간 방치하여 침전물을 생성시키고 원심 분리기를 사용하여 8,000rpm에서 30분간 원심 분리하여 침전물을 취한 후 냉동건조기를 사용하여 냉동 건조하여 얻은 분말을 시료 A로 하였다. 균사체는 95℃에서 4시간 동안 환류 냉각시키며 물로 추출하고 감압 여과한 후 잔사는 버리고, 여액은 앞의 방법과 동일한 조작을 하여 분말화하였으며, 이를 시료 B로 하였다.The culture solution was filtered under reduced pressure according to the method of Park et al. (1979), and the filtrate and mycelium were separated. The filtrate was concentrated and ethanol of 3 times the volume of the concentrate was added thereto, and the precipitate was left at 4 ° C. for 1 day to generate a precipitate. The precipitate was collected by centrifugation at rpm for 30 minutes, and then freeze-dried using a freeze dryer to obtain Sample A. The mycelium was refluxed for 4 hours at 95 ° C., extracted with water, filtered under reduced pressure, and then the residue was discarded. The filtrate was powdered by the same operation as in the previous method.

시료 A와 B를 합해 총 조단백 다당류로 하였다.Samples A and B were combined to obtain total crude protein polysaccharide.

항암성분의 분석Analysis of Anticancer Ingredients

1) 항암성분의 다당류 함량 및 구성당류 분석1) Analysis of polysaccharide content and constituent sugars of anticancer components

다당류 함량은 포도당을 대조용으로 하여 안트론 시험을 행하였다. 포도당과 시료에 대해 안트론 반응을 시켜 620nm에서 흡광도를 측정한 후 감량곡선을 작성하였다. 포도당을 표준으로 해서 작성한 검량곡선을 사용하여 시료중의 다당류 함량을 계산하였다.The polysaccharide content was subjected to the antron test with glucose as a control. Anthrone reaction was performed on the glucose and the sample to measure absorbance at 620 nm, and then a weight loss curve was prepared. The polysaccharide content in the sample was calculated using a calibration curve prepared with glucose as a standard.

구성당류는 시료 10mg을 0.1N HCl 2ml에 용해시키고 앰풀에 넣은 후 질소를 충진시키고 밀봉한 뒤 100±5℃에서 5시간 가수분해 시켰다. 여과하여 냉동 건조하고 다음과 같은 조건하에서 H.P.L.C.를 행하였다.Constituent sugar was dissolved in 2ml of 0.1N HCl 2ml and put in ampoule, filled with nitrogen and sealed and hydrolyzed at 100 ± 5 ℃ for 5 hours. After filtration and freeze drying, H.P.L.C. was carried out under the following conditions.

칼럼 : μBondapak carbohydrate analyslsColumn: μBondapak carbohydrate analysls

용매 : Ac CN/H2O/BuOH(80/20/15)Solvent: Ac CN / H 2 O / BuOH (80/20/15)

유속 : 1.5ml/mlnFlow rate: 1.5ml / mln

검출기 : Rl(X8)Detector: Rl (X8)

챠트속도 : 1cm/mlnChart Speed: 1cm / mln

기지농도의 각 표준품을 같은 방법으로 H.P.L.C.를 행하여 크로마토 그라프상 보지시간을 표준품과 시료를 비교 동정하여, 시료의 단당류를 확인하고 정량하였다.H.P.L.C. was carried out in the same manner for each standard product having a known concentration, and chromatographic holding time was compared and identified between the standard product and the sample to identify and quantify the monosaccharides in the sample.

2) 항암성분의 단백질 함량 및 구성 아미노산 분석2) Analysis of Protein Content and Constituent Amino Acids of Anticancer Components

단백질 함량은 알부민을 대조로 하여 롤리-포린 시험을 행하였다. 알부민과 시료에 대해 각각 롤리포린 반응을 실시한 후 U.V. 스펙트로포토메터를 사용하여 750nm에서 흡광도를 측정하였다. 알부민을 표준으로 해서 작성된 검량곡선을 사용하여 시료중의 단백질 함량을 계산하였다.The protein content was subjected to the Raleigh-porin test with albumin as a control. The albumin and the sample were each subjected to a lololipoline reaction, followed by U.V. Absorbance was measured at 750 nm using a spectrophotometer. The protein content in the sample was calculated using a calibration curve prepared with albumin as a standard.

구성 아미노산을 시료를 가수 분해시킨 뒤 아미노산 자동분석기로 분석하였다. 시료 20mg을 5ml의 6N-HCl에 용해시켜 앰풀에 넣고 질소를 충진하고 밀봉시켰다. 이것을 110±5℃에서 24시간 동안 가수 분해시킨 후 여과하여 침전을 제거하고 감압 농축하여 건조시켰다. 이것을 0.02N-HCl 2ml에 용해시킨 후 40μl를 아미노산 자동분석기에 주입하여 분석하였다.The constituent amino acids were hydrolyzed and analyzed with an amino acid autoanalyzer. 20 mg of sample was dissolved in 5 ml of 6N-HCl, placed in ampoules, filled with nitrogen and sealed. This was hydrolyzed at 110 ± 5 ° C. for 24 hours, filtered to remove precipitates, and concentrated under reduced pressure to dryness. After dissolving this in 2 ml of 0.02N-HCl, 40 μl was injected into an amino acid autoanalyzer and analyzed.

아미노산 자동분석기는 히다찌 모델 835를 사용하였으며 분석조건은 다음과 같다.The amino acid autoanalyzer used Hitachi model 835 and the analysis conditions were as follows.

칼럼 : 2.6×150mmColumn: 2.6 × 150mm

이온교환수지 : #2619(히다찌) 완충용액 0.225 ml/mlnIon-exchange resin: 0.225 ml / mln of # 2619 (Hitachi) buffer

닌히드린 0.3 ml/mlnNinhydrin 0.3 ml / mln

분석서클타임 :70mlnAnalysis circle time: 70mln

칼럼압 : 80-130kg/㎠Column pressure: 80-130kg / ㎠

닌히드린압 : 15-35kg/㎠Ninhydrin pressure: 15-35kg / ㎠

칼럼온도 : 53℃Column Temperature: 53 ℃

N2개스압 : 0.28kg/㎠N 2 gas pressure: 0.28kg / ㎠

반응조 온도 : 98℃Reactor temperature: 98 ℃

파장 : 570nm, 440nmWavelength: 570nm, 440nm

같은 조건으로 표준아미노산을 3nmol/5μl의 농도로 40μl를 분석기에 주입시켜 크로마토그람을 얻은 후 시료의 그것과 비교하여 구성 아미노산을 확인하였고, 피크높이법에 의해 각 아미노산의 구성비를 산출하였다.Under the same conditions, 40 μl of standard amino acid was injected into the analyzer at a concentration of 3 nmol / 5 μl to obtain a chromatogram, and the constituent amino acids were identified by comparison with that of the sample, and the composition ratio of each amino acid was calculated by the peak height method.

항암실험Anticancer test

본 실험에 사용한 동물은 서울대학교 동물사육장에서 구입한 25g인 숫컷 A-straln 마우스를 사용하였다. 마우스 50마리의 겨드랑이에 사르코마 180세포 현탁액 0.1ml/(1×106cell)를 주사하였다. 각 군은 10마리씩으로 하고 대조군, 20mg/kg/day l.p, 100mg/kg/day l.p.의 3군으로 하였다. 암세포를 이식하고 3일 경과 후 연속하여 약물을 10주일간 주사하고 암 이식날부터 31일째 쥐를 모두 치사시키고 고형암을 적출 해내어 암의 무게를 측정하여 평균치를 얻었다.Animals used in this experiment were male A-straln mice, 25 g, purchased from Seoul National University. 50 mice were injected with 0.1 ml / (1 × 10 6 cells) of a Sarcoma 180 cell suspension. Each group was made up of 10 animals, and 3 groups of control group, 20 mg / kg / day lp, and 100 mg / kg / day lp. Three days after the cancer cell transplantation, the drug was injected continuously for 10 weeks, and all rats were killed at 31 days from the day of the cancer transplantation.

항암작용의 지표로서 종양의 저지백분율(l.R.=lnhlbltlon ratlo)을 다음과 같은 식에 의해 구하였다.As a marker of anticancer activity, the percentage of tumor inhibition (l.R. = lnhlbltlon ratlo) was calculated by the following equation.

지지백분율,

Figure kpo00001
Percentage Supported,
Figure kpo00001

Cw=대조군의 평균 종양 무게Cw = mean tumor weight of control

Tw=처치군의 평균 종양 무게Tw = mean tumor weight of treatment group

항암성분이 면역에 미치는 영향Effect of Anticancer Compounds on Immunity

1) 실험재료1) Experimental material

마우스는 항암실험과 동일한 마우스를 사용하였다.The mouse used the same mouse as the anticancer experiment.

배양여액과 균사체로부터 추출한 시료를 합한 단백 결합 다당류를 시료로 사용하였다.Protein-bound polysaccharide, which was a combination of the culture filtrate and the sample extracted from the mycelium, was used as a sample.

비장세포를 현탁시키는데 사용한 밸런스 염류액(=B.S.S)은 다음과 같이 조제하였다.Balanced saline solution (= B.S.S) used to suspend splenocytes was prepared as follows.

용액 l은 포도당 10g, KH2PO40.6g, Na2HPO41.85g, 0.5% 페놀래드 용액 2ml를 탈이온수 1l에 녹였다.Solution 1 was dissolved in 10 g of glucose, 0.6 g of KH 2 PO 4 , 1.85 g of Na 2 HPO 4 , and 2 ml of 0.5% phenolrad solution in 1 l of deionized water.

용액 Ⅱ는 CaCl21.86g, KCl 4.0g, NaCl 80g, MgCl22.0g, MgSO42.0g을 탈이온수 1l에 녹였다. 사용시 증류수 800ml, 용액 Ⅰ100ml, 용액 Ⅱ 100ml를 섞어서 pH 7.2로 하여 사용하였다.Solution II dissolved 1.86 g of CaCl 2 , 4.0 g of KCl, 80 g of NaCl, 2.0 g of MgCl 2, and 2.0 g of MgSO 4 in 1 L of deionized water. In use, 800 ml of distilled water, 100 ml of solution I, and 100 ml of solution II were mixed and used at pH 7.2.

항원을 현탁시키는데 사용한 완충액(Conjugatlon buffer)은 NaCl 4.38g, KH2PO42.44g, Na2HPO410.00g을 탈이온수 1l에 녹여 사용하였다.Conjugatlon buffer used to suspend the antigen was used by dissolving 4.38 g of NaCl, 2.44 g of KH 2 PO 4 , and 10.00 g of Na 2 HPO 4 in 1 l of deionized water.

면양적혈구(sheep red blood cell=S.R.B.C)는 엘시버액(Alsever's solutln)에 저장된 것을 사용 전에 4회 완충액으로 씻어서 사용하였다.Sheep red blood cells (S.R.B.C) were stored in Alsever's solutln and washed with buffer four times before use.

보체로써는 기니아 피그 보체(Gulnea plg complement; M.A. Bloproducts사 제품)를 사용하였으며, 슬라이드 챔버는 25mm×7mm이었고, 바셀린과 파라핀의 비는 1 : 1이었다.As a complement, a guinea pig complement (Gulnea plg complement; manufactured by M.A. Bloproducts) was used. The slide chamber was 25 mm × 7 mm, and the ratio of petrolatum and paraffin was 1: 1.

2) 실험방법2) Experiment Method

커닝햄(cunnlngham, 1973) 및 제론(Jerne, 1974)의 방법에 따라 플래크 어세이를 행하였다.Plaque assays were performed according to the methods of Cunnlngham (1973) and Jerone (1974).

24마리의 마우스를 6마리씩 4군으로 나누고 시료투여군으로서 2군에는 단백결합 다당류(50mg/kg/day/l.p.)를 대조군으로 나머지 2군에는 생리식염수를 5일간 l.p.로 투여하였다.Twenty-four mice were divided into four groups of six animals each, and as a sample administration group, the protein-bound polysaccharide (50 mg / kg / day / l.p.) Was administered as a control group, and the other two groups were administered saline with l.p. for 5 days.

최종 투여 후 10일이 지난 뒤어 투여군 중 1군과 대조군 중 1군에 면양 적혈구 1×107세포를 마우스에 주사하여 면역시켰다. 나머지 2군에는 생리 식염수를 투여하였다.Ten days after the final administration, mice were immunized with 1 × 10 7 cells of sheep red blood cells in one of the administration groups and one of the control groups. Physiological saline was administered to the remaining two groups.

그후 5일이 지난 후에 마우스의 비장을 분리하여 BSS 10ml를 넣어 균질화하고 2,000rpm에서 5분간 원심 분리하여 비장 세포를 침전시킨 후 4℃에서 0.83% NH4Cl 5ml를 가하여 적혈구를 용혈시켰다.After 5 days, the spleens of the mice were separated, homogenized with 10 ml of BSS, centrifuged at 2,000 rpm for 5 minutes to precipitate splenocytes, and red blood cells were hemolyzed by adding 0.83% NH 4 Cl 5 ml at 4 ° C.

이것을 다시 BSS 10ml로 3회 세척하고 일정량의 BSS를 가하여 재현탁시켜 총 세포수를 계산하였으며, 그 현탁액의 일부를 취하여 106cell/ml의 비장세포 현탁액을 만들었다.This was again washed three times with 10 ml of BSS and resuspended with the addition of a certain amount of BSS to calculate the total cell number. A portion of the suspension was taken to make a 10 6 cell / ml splenocyte suspension.

소시험관에 BSS 30μl, 보체 20μl, 20% S.R.B.C. 10μl, 비장세포 현탁액 100μl를 넣고 잘 혼합하여 슬라이드 챔버에 옮겨 바셀린-파리핀으로 봉하고 37℃에서 2시간 배양한 다음, 형성된 용혈반의 수를 세었다.30 μl of BSS, 20 μl of complement, 20% S.R.B.C. 10 μl, 100 μl of the splenocyte suspension were added, mixed well, transferred to a slide chamber, sealed with petroleum jelly and paraffin, incubated at 37 ° C. for 2 hours, and the number of hemolytic plaques formed was counted.

[실시예 1-10]Example 1-10

본 실시예들은 다음 표 l의 조성을 가지는 배지를 사용하여 탄소원으로 전분의 이용 가능성을 검토하기 위하여 글루코오즈를 대조로 하고, 전분을 각 농도별로 첨가하여 전술한 2차 액내 진탕 배양법으로 14일간 배양하여 그 항암성분을 전술한 추출법 및 분석법으로 분석한 것으로 그 결과는 표 1과 같다.These examples were prepared using glucose having a composition shown in Table 1 as a control to examine the availability of starch as a carbon source, adding starch to each concentration, and incubating for 14 days with the above-described secondary incubation culture. The anticancer component was analyzed by the aforementioned extraction and analysis methods, and the results are shown in Table 1.

[표 Ⅰ]TABLE I

배지 1-10의 조성Composition of Medium 1-10

Figure kpo00002
Figure kpo00002

* B.M.S.(기본광물액) : FeSO4·7H2O 100mg* BMS (basic mineral solution): FeSO 4 · 7H 2 O 100mg

MnCl2·4H2O 70mgMnCl 2 4H 2 O 70mg

ZnSO4·7H2O 40mgZnSO 4 7H 2 O 40 mg

CuSO4·5H2O 10mgCuSO 4 5H 2 O 10mg

증류수 100ml100ml of distilled water

**최종부피 : 배지 성분에 증류수를 가한 후의 부피이다.** Final volume: The volume after distilled water is added to the medium component.

[실시예 11-20]Example 11-20

본 실시예들은 탄소원으로 당밀을 각 농도별로 첨가한 다음의 표 Ⅱ의 배지를 사용하여 전술한 2차 액내 진탕 배양방법으로 14일간 배양하고 그 항암성분을 전술한 추출법 및 분석한 것으로 그 결과는 표 1과 같다.The present examples were obtained by adding molasses as a carbon source for each concentration, followed by incubation for 14 days using the above-described secondary liquid shaking culture method using the medium of Table II. The anticancer components were extracted and analyzed as described above. Same as 1.

[표 Ⅱ]TABLE II

배지 11-20의 조성Composition of Medium 11-20

Figure kpo00003
Figure kpo00003

[실시예 21-30]Example 21-30

본 실시예들은 탄소원으로 구기자박 추출물을 각 농도별로 가한 다음 표 Ⅲ의 배지 이용 가능성을 검토한 것으로 전술한 2차 액내 진탕 배양법으로 14일간 배양하고 그 항암성분을 전술한 추출법 및 분석법으로 분석하여 그 결과를 표 1에 표시하였다.In the present examples, the Gojijak extract was added to each concentration as a carbon source, and then the availability of the medium in Table III was examined. The culture was carried out for 14 days by the above-mentioned secondary liquid shaking culture, and the anticancer components were analyzed by the above extraction and analysis method. The results are shown in Table 1.

[표 Ⅲ]TABLE III

배지 21-30의 조성Composition of medium 21-30

Figure kpo00004
Figure kpo00004

* 구기자박 추출액 : 구기자를 물로 추출한 잔류물에 5배의 물을 가해 95-100℃로 4시간 추출한 액* Goji berry extract: Extracted goji berry with water 5 times to the residue extracted at 95-100 ℃ for 4 hours

[표 1]TABLE 1

여러가지 탄소원을 이용한 배양액에서 생산된 균사체 및 단백 결합 다당류(PBP)의 비교Comparison of Mycelia and Protein Bound Polysaccharides (PBP) Produced in Culture Media Using Various Carbon Sources

Figure kpo00005
Figure kpo00005

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 31-40]Example 31-40

본 실시예들은 질소원으로 탈지대두분을 각 농도별로 첨가한 다음 표 Ⅳ의 배지를 사용하여 전술한 2차 액내 진탕 배양방법으로 14일간 배양하고 그 항암성분을 전술한 추출법 및 분석법으로 분석하여 그 결과를 표 2에 표시하였다.The present examples were added to each concentration of skim soy flour as a nitrogen source, and then cultured for 14 days by the above-described secondary liquid shaking culture method using the medium of Table IV, and analyzed the anticancer components by the above extraction and analysis method. Is shown in Table 2.

[표 Ⅳ]Table IV

배지 31-40의 조성Composition of medium 31-40

Figure kpo00006
Figure kpo00006

[실시예 41-50]Example 41-50

본 실시예들은 질소원으로 C.S.L.(콘스팁리커)을 각 농도별로 첨가한 다음 표 Ⅴ의 배지를 사용하여 전술한 2차 액내 진탕 배양법으로 14일간 배양하고 그 항암성분을 추출 및 분석한 것으로 그 결과는 표 2와 같다.The present examples were added to each concentration of CSL (conestipikriker) as a nitrogen source, followed by incubation for 14 days using the above-described secondary liquid shaking culture method using the medium of Table V, and the anticancer components were extracted and analyzed. Table 2 is as follows.

[표 Ⅴ]TABLE V

배지 41-50의 조성Composition of medium 41-50

Figure kpo00007
Figure kpo00007

[표 2]TABLE 2

질소원으로 탈지대부분이나 C.S.L.을 사용한 배양액에서 생산되 균사체 및 단백결합 다당류(PBP)의 비교Comparison of Mycelia and Protein-bound Polysaccharides (PBP) Produced in Cultured Skim Using Most Nitrogen Sources or C.S.L.

Figure kpo00008
Figure kpo00008

Figure kpo00009
Figure kpo00009

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 51-60]Example 51-60

본 실시예들은 인삼박 추출물을 배지로서의 이용 가능성을 검토하기 위해 기존배지의 농도를 변화시킨 표 Ⅵ의 배지를 사용, 배양실험을 행한 것으로 이 결과를 표 3에 표시하였으며 기존 배지에 인삼박 추출물을 39% 가한 것이 균사생장이 양호함을 알았다.In the present examples, the results of the culture experiments were performed using the culture medium of Table VI which changed the concentration of the existing medium to examine the availability of ginseng meal extract as a medium. 39% added showed good mycelial growth.

[표 Ⅵ]Table VI

배지 51-60의 조성The composition of the medium 51-60

Figure kpo00010
Figure kpo00010

* A액 : 글루코오스 50g과 펩톤 20g을 증류수에 녹여 1000ml로 한 액.* Solution A: 50g of glucose and 20g of peptone are dissolved in distilled water to make 1000ml.

인삼박추출액 : 인삼근의 알콜 추출 잔류물에 5배의 물을 가해 95-100℃로 4시간 추출한 액.Panax ginseng extract: A solution extracted at 95-100 ℃ for 4 hours by adding 5 times water to alcohol extract residue of ginseng root.

[표 3]TABLE 3

인삼박 추출물의 배지로서 이용 가능성을 검토한 결과 아래와 같으며, 이는 완전 배지로서 이용은 할 수 없으나 적당 농도에서 균사의 생장을 촉진시키는 작용이 있는 것으로 생각되어 다른 배지 성분에 첨가하여 사용할 수 있을 것으로 생각된다.As a result of examining the applicability of ginseng gourd extract as a medium, it is as follows, which is not available as a complete medium, but it is thought to have an effect of promoting the growth of mycelia at an appropriate concentration, and thus it can be added to other medium components. I think.

Figure kpo00011
Figure kpo00011

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 61-72]Example 61-72

본 실시예들은 값싼 산업용 배지에서 비교적 균사체의 생장이 우수한 배지번호 4-9화 6-8을 조합하여 인과 금속이온의 농도를 변화시킨 다음 표 Ⅶ의 배지에 배양실험을 한 것으로 그 결과는 표 4와 같다.These Examples were cultured in the medium of Table VII by changing the concentration of phosphorus and metal ions by combining medium Nos. 4-9 and 6-8 with excellent mycelium growth in a cheap industrial medium. Same as

[표 Ⅶ][Table VII]

배지 61-72의 조성Composition of Medium 61-72

Figure kpo00012
Figure kpo00012

* 구기자박추출액 -표 참조* Goji berry extract-see table

[표 4]TABLE 4

인 및 금속 이온농도에 따른 균사체의 생장 및 PBP 수율Growth and PBP Yield of Mycelium by Phosphorus and Metal Ion Concentration

Figure kpo00013
Figure kpo00013

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 73-81]Example 73-81

본 실시예는 표 Ⅶ배지에서 실험한 결과 얻어진 최적 배지조건에서 pH만 변화시킨 표 Ⅷ의 배지를 사용하여 배양실험을 한 것으로 그 결과는 표 5와 같다.In this example, the culture experiment was performed using the culture medium of Table VII in which only pH was changed under the optimum medium conditions obtained as a result of the experiment in Table VII medium, and the results are shown in Table 5.

[표 Ⅷ][Table VII]

배지 73-81의 조성The composition of the badge 73-81

Figure kpo00014
Figure kpo00014

* 구기자박추출액 -표 Ⅲ참조* Goji berry extract-see Table III

[표 5]TABLE 5

pH 변화에 따른 균사체의 생산 및 PBP수율Mycelial Production and PBP Yield with pH Change

Figure kpo00015
Figure kpo00015

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 82]Example 82

본 실시예는 배양시간에 따른 균사체의 생장량을 비교하기 위하여, 배지 9-1에서 9-9 중 균사체 생장이 가장 양호한 8-5를 사용하여 진탕 배양하면서 시간경과에 따른 균사 생장량을 측정하였다.In this example, in order to compare the mycelial growth according to the culture time, the mycelial growth over time was measured while shaking culture using 8-5 having the best mycelium growth in the medium 9-1 to 9-9.

그 결과는 표 6과 같다.The results are shown in Table 6.

[표 6]TABLE 6

Figure kpo00016
Figure kpo00016

단위는 g/100ml(배양액)임.The unit is g / 100ml (culture medium).

[실시예 83]Example 83

항암성분의 분석Analysis of Anticancer Ingredients

1) 항암성분의 다당류 함량 및 구성당류의 분석1) Analysis of polysaccharide content and constituent sugars of anticancer components

안트론법에 따라 실험한 후 스펙트로 포토메터에 의한 다당류 함량 및 H.P.L.C.에 의한 구성당류의 분석결과는 표 7, 표 8 및 제1도에서 나타난 바와 같다.The results of analysis of the polysaccharide content by spectrophotometer and the constituent sugar by H.P.L.C. after experiment according to the antron method are shown in Table 7, Table 8 and FIG.

2) 항암성분의 단백질 함량 및 아미노산 분석2) Protein Content and Amino Acid Analysis of Anticancer Components

롤리-포린 시험 후 U.V. 스펙트로 포토메터에 의해 계산된 단백질 함량 및 가수분해 후 아미노산 자동 분석기에 의해 분석된 아미노산 조성은 표 9, 표 10 제2도 및 제3도에 나타난 바와 같다.U.V. after the Raleigh-Porrin test. Protein content calculated by the spectrophotometer and amino acid composition analyzed by the amino acid autoanalyzer after hydrolysis are shown in Table 9, Table 10 2 and 3.

[표 7]TABLE 7

단백결합 다당류의 함량Protein-bound polysaccharide content

Figure kpo00017
Figure kpo00017

[표 8]TABLE 8

단당류의 함량Monosaccharide Content

Figure kpo00018
Figure kpo00018

[표 9]TABLE 9

단백결합 다당류의 단백질 함량Protein Content of Protein-bound Polysaccharides

Figure kpo00019
Figure kpo00019

[표 10]TABLE 10

단백결합 다당류의 아미노산 함량Amino Acid Content of Protein-bound Polysaccharides

Figure kpo00020
Figure kpo00020

[실험예 1]Experimental Example 1

항암실험Anticancer test

마우수에 이식한 사르코마-180을 이용한 항암실험 결과에서 대조군에 비하여 처치군에서 종양 무게가 훨씬 작아 시료가 항암성분을 가지고 있음을 알 수 있었다(표 11).As a result of the anticancer test using Sarcoma-180 implanted in the cow water, the tumor weight was much smaller in the treatment group than the control group, indicating that the sample had anticancer component (Table 11).

[표 11]TABLE 11

사르코마-180을 접종한 마우스에 대한 단백결합 다당류의 효과Effect of Protein Binding Polysaccharide on Sarcoma-180 Inoculated Mice

Figure kpo00021
Figure kpo00021

** 평균±표준편차** mean ± standard deviation

** 통계학상 큰 의미(P<0.01)** Statistical significance (P <0.01)

[실험예 2]Experimental Example 2

항암성분의 면역촉진효과 실험Immunostimulating Effect Test of Anticancer Components

플레크에 에세이에 의한 항암성분의 면역 촉진효과에 대한 결과는 표 12와 같다. 표 12에서 보면 총 비장세포의 수는 현저하지는 않다 할지라도 용혈반형성 세포의 수가 현저히 증가한 것으로 나타났다.Table 12 shows the results of the immune-stimulating effect of the anticancer component by the assay. In Table 12, although the total splenocyte count was not significant, the number of hemolytic plaque cells increased significantly.

[표 12]TABLE 12

면약 적혈구로 면역된 마우스의 비장에서 용혈성 플래크 형성 세포Hemolytic plaque forming cells in the spleen of mice immunized with exempt red blood cells

Figure kpo00022
Figure kpo00022

Claims (1)

만년버섯 [Ganoderma Lucldum(Fr.) Karsten]의 균사체를 무기염을 함유하는 액체 배지에 배양하여 항암성 단백다당류를 제조하는 공지의 방법에 있어서, 그 배지의 성분 중 탄소원 및 질소원으로 구기자박 추출액 85v/v%, 콘스팁리커 1.5v/v%를 첨가하고 pH를 5.5 내지 6.0으로 한 배지를 사용하는 항암성 단백다당류의 제조방법.In a known method for producing anticancer protein polysaccharides by culturing the mycelium of Ganoderma Lucldum (Fr. Karsten) in a liquid medium containing an inorganic salt, gojijak extract extract using a carbon source and a nitrogen source among the components of the medium. / v%, a method for producing an anticancer protein polysaccharide using a medium having added conspitip liquor 1.5v / v% and pH of 5.5 to 6.0.
KR1019840005339A 1984-08-28 1984-08-28 Manufacturing method of anti-cancerous polypeptide KR870001416B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019840005339A KR870001416B1 (en) 1984-08-28 1984-08-28 Manufacturing method of anti-cancerous polypeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019840005339A KR870001416B1 (en) 1984-08-28 1984-08-28 Manufacturing method of anti-cancerous polypeptide

Publications (2)

Publication Number Publication Date
KR860001878A KR860001878A (en) 1986-03-24
KR870001416B1 true KR870001416B1 (en) 1987-07-30

Family

ID=19235258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005339A KR870001416B1 (en) 1984-08-28 1984-08-28 Manufacturing method of anti-cancerous polypeptide

Country Status (1)

Country Link
KR (1) KR870001416B1 (en)

Also Published As

Publication number Publication date
KR860001878A (en) 1986-03-24

Similar Documents

Publication Publication Date Title
Hino et al. Studies of an immunomodulator, swainsonine I. Enhancement of immune response by swainsonine in vitro
US5385832A (en) Method for obtaining highly pure beta 1,3-glucan from euglena
US6383799B1 (en) Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom
Horecker et al. The enzymatic formation of sedoheptulose phosphate from pentose phosphate
WO1993000924A1 (en) Use of lipases to produce drugs
CA1184899A (en) Glycoprotein
KR100197446B1 (en) Anti-cancer immunoactive polysaccharides separated from phellinus linteus and process for the preparation thereof
KR870001416B1 (en) Manufacturing method of anti-cancerous polypeptide
RU2082755C1 (en) Ganoderma lucidum strain which is proteoglycane g009 producer having antitumor and immune-stimulating activity
EP0331821B1 (en) Antiviral agent
KR920010763B1 (en) Polyglycoprotein, extracted from ganoderma lucidum, having antitumoric effect
KR20020081824A (en) Process for Preparing Lectin Drived from Fomitella fraxinea
KR970009150B1 (en) Liquid culture of phellinus linteus and preparation process ofanticancer material
Shin et al. Production of Anti-Complementary Exopolysaccharides from Submerged Culture of Flammulina velutipes.
JPH04300898A (en) New glycoprotein conjugate and production thereof
KR20040032478A (en) Application and production of muco-polysaccharide by submerged culture of novel Grifola frondosa HB0071 KCTC 10337BP
KR100317659B1 (en) Method for culturing Phellinus linteus on the solid medium
RU2824212C1 (en) Method of producing peptide fraction from water-soluble proteins of microalgae, having antibiotic properties
KR840000505B1 (en) Process for preparing antitumor polysaccharide
US4409385A (en) Polysaccharides having anticarcinogenic activity and method for producing same
KR20050036004A (en) Process for preparing nontoxic rhus verniciflua extract, and the use of the extract
KR0143512B1 (en) Immunopotentive agents and isolating methods from cultivated ganoderma lucidum
Phipps et al. Effect of nitrogen nutrition on the free amino acid pool of Choanephora cucurbitarum and parasitism by two haustorial mycoparasites
CA1127572A (en) Polysaccharides having anticarcinogenic activity and method for producing same
Bobbitt et al. A survey of Aspergillus and Penicillium species producing an exocellular nigeran-protein complex

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030708

Year of fee payment: 17

LAPS Lapse due to unpaid annual fee